The 8th meeting of the first council of China Liver Health (CLH) was held in the health building of Peking University Health Science Center on Dec 27, 2019. Academician Zhuang Hui (honorary chairman of CLH), chairman Wei Lai, director Li Mingyang, deputy director Shen Yingsheng, Prof. Li Jie (council member), Prof. Li Tong (council member), Prof. Liu Xueen (council member), Ma Lili (council member), Guo Hui (council member) and supervisor Liu Qiang attended the meeting. Deputy director Shen Yingsheng presided over the meeting.
Group photo of council members
Chairman Wei Lai In the speech, chairman Wei Lai pointed out that since the establishment in September, 2016, and under the guidance of academician Zhuang Hui, CLH had made great achievements and carried out cooperation with international and domestic partnerships. State departments, especially the healthcare security department, and the WHO attach great importance to hepatitis C prevention and control, make efforts to analyze hepatitis C situation and accelerate the inclusion of hepatitis C treatment into medical insurance coverage. Leaders from the Bureau of Disease Prevention and Control under the National Health Commission, the WHO, and Chinese Center for Disease Control and Prevention have paid attention to and participated in HCV screening and training activities sponsored by CLH for several times. Director Li Mingyang promotes good cooperation with local health commissions, hospitals and doctors.
Director Li Mingyang Director Li Mingyang reviewed the main work and key projects carried out by CLH during the past three years, and mainly introduced the China Hepatitis C Elimination Alliance Public Welfare Project, training sessions on WHO guideline for hepatitis C prevention and control, exchanges with fatty liver centers, financial support from the central government and participation in social service projects.
Deputy director Shen Yingsheng
Council member Ma Lili Deputy director Shen Yingsheng reported the situation of party members. CLH has set up a party branch jointly with the Bethune Spirit Research Association and Tiannuo Charitable Foundation. Council member Ma Lili reported financial operations of CLH. CLH passed all annual inspections from 2016 to 2018. At the end of 2018, CLH was granted the non-profit tax exempt certificate. Expenditure on operational activities in 2019 reached 11.72 million yuan and was higher than that in the past years.
Prof. Liu Xueen introduced the hepatitis B testing and vaccination project for children carried out in Tibetan areas in 2019. Prof. Li Jie introduced the upcoming hepatitis B screening and vaccination campaign to be launched in universities in 2020. Prof. Li Tong introduced the results of medical training sessions under China Hepatitis C Elimination Alliance Public Welfare Project.
Council members exchanged opinions on the development plan of CLH.
Honorary chairman Zhuang Hui Honorary chairman Zhuang Hui made closing remarks and expressed appreciation for the efforts made by council members. He pointed out that the National Demonstration Project of Liver Disease Relief in Children sponsored by CLH in northwest China in 2015, which provided hepatitis testing and vaccination for local middle school students, was of great significance and ensured that the care from the Party reached the public. In 2016, interferon drugs worth more than 100 million yuan were distributed to hepatitis B and hepatitis C patients, bring them tangible benefits. A series of hepatitis C elimination action were carried out, including training, screening, treatment, follow-up and policy-making, and played an important role in pushing the government to include hepatitis C drugs into medical insurance coverage. With solid work, CLH has established a good image in the health industry. This meeting has important implications for the future development of CLH. In the future, CLH will continue to actively respond to the call of national strategies, probe into the development trend of the health industry and contribute to liver health promotion. |
关注官方微信 
